Association of prior treatment with nitrogen-containing bisphosphonates on outcomes of COVID-19 positive patients von Lee, R.H., Curtis, J., Drake, M.T., Bobo Tanner, S., Lenert, L., Schmader, K., Pieper, C., North, R., Lyles, K.W.

Volltext

Persistent effect of zoledronic acid in reducing the risk for fractures: pooled analysis of horizon-PFT and RFT von Black, D, Boonen, S, Lyles, K.W, Bucci-Rechtweg, C, Su, G

Volltext

Long-term efficacy of zoledronic acid compared with risedronate in Paget's disease von Reid, I, Lyles, K.W, Su, G, Brown, J, Walsh, J, del Pino, J, Miller, P, Fraser, W.D, Gall, M, Saidi, Y, Bucci-Rechtweg, C, Hosking, D

Volltext

Once-yearly treatment with zoledronic acid continues to be effective in old age von Reid, I, Boonen, S, Black, D.M, Colon-Emeric, C, Eastell, R, Magaziner, J, Mesenbrink, P, Eriksen, E.F, Lyles, K.W

Volltext

Zoledronic acid reduces the rate of clinical fractures after surgical repair of a hip fracture regardless of the Pretreatment bone mineral density von Lyles, K.W., Bauer, D.C., Colon-Emeric, C.S., Pieper, C.F., Cummings, S.R., Black, D.M.

Volltext

Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis von Boonen, S, Eastell, R, Su, G, Mesenbrink, P, Cosman, F, Cauley, J.A, Reid, I.R, Claessens, F, Vanderschueren, D, Lyles, K.W, Black, D.M

Volltext bestellen